FindTrial
Sign In

Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Branch Retinal Vein Occlusion

Three Injections of Intravitreal Bevasizumab Versus Two Injections of Intravitreal Triamcinolone in the Management of Branch Retinal Vein Occlusion

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01044329
Acronym
BRVO
Enrollment
90
Registered
2010-01-07
Start date
2010-01-31
Completion date
2010-12-31
Last updated
2010-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Branch Retinal Vein Occlusion

Brief summary

This randomized clinical trial is conducted to evaluate the effect of three intravitreal injections of bevasizumab versus two intravitreal injections of triamcinolone in acute retinal vein occlusion. The outcomes are visual acuity and central macular thickness. The follow-up time is 6 months.

Interventions

DRUGBevacizumab

Intravitreal, 1.25 mg, 3 times, one month apart.

DRUGTriamcinolone Acetonide

Intravitreal, 2 mg, 2 times, two months apart.

Sponsors

Labbafinejad Medical Center
CollaboratorOTHER
Shahid Beheshti University of Medical Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Recent onset (less than 3 months) BRVO

Exclusion criteria

* Any previous intervention

Design outcomes

Primary

MeasureTime frame
Visual acuity6 months

Secondary

MeasureTime frame
central macular thickness6 months

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026